Welcome to our dedicated page for Climb Bio SEC filings (Ticker: CLYM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Climb Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Climb Bio's regulatory disclosures and financial reporting.
Climb Bio director and 10% owner entities affiliated with RA Capital reported a major restructuring of their holdings and additional open-market share purchases. On December 11, 2025, RA Capital Healthcare Fund, L.P. exchanged 20,440,000 shares of Climb Bio common stock for a pre-funded warrant exercisable for up to 20,440,000 shares at an exercise price of $0.0001 per share, for no additional consideration.
The filing also reports open-market purchases of Climb Bio common stock: 213,099 shares on December 11, 2025 at a weighted average price of $2.18 per share and 101,462 shares on December 12, 2025 at a weighted average price of $2.86. The warrant has no expiration date, is exercisable immediately, and includes a 33.0% beneficial ownership cap, limiting how many shares can be exercised based on total outstanding stock. Climb Bio shares are held across multiple RA Capital funds and a separately managed account, with beneficial ownership relationships detailed among the affiliated entities.
Climb Bio (CLYM) reported third-quarter results marked by higher R&D investment and a solid liquidity position. Q3 net loss was $12.9 million, driven by research and development of $9.1 million and general and administrative of $5.8 million. For the nine months, net loss was $42.3 million.
Cash, cash equivalents and marketable securities were $175.8 million as of September 30, 2025, with stockholders’ equity of $177.0 million. Operating cash use was $38.7 million year to date. The company established an at‑the‑market program for up to $22.4 million and did not sell shares during the quarter. Shares outstanding were 68,184,435 as of October 31, 2025.
Pipeline progress included FDA clearance for a Phase 2 pMN study of budoprutug and an open‑label Phase 1b/2a study in ITP, with sites being activated and patients being enrolled and dosed. Climb also recorded a $9.0 million upfront expense earlier in the year for the CLYM116 license and noted milestone frameworks with Acelyrin, CRH and ProBioGen tied to future development and sales events.
Climb Bio (CLYM) filed an 8-K announcing new long-term follow-up data for budoprutug, an anti‑CD19 monoclonal antibody in development for B‑cell mediated diseases. An abstract reports results from a previously conducted Phase 1b trial (NCT04652570) in primary membranous nephropathy.
The data showed long-term control of proteinuria for up to three years after initial dosing in four patients who received up to four doses of budoprutug. Three patients required no further immunosuppressive treatment during follow-up. No treatment‑related adverse events grade 3 or higher were observed in the trial.
The company’s forward‑looking statements section references development plans for budoprutug and CLYM116 and outlines risks including clinical progress, regulatory approvals, competition, intellectual property, and capital needs.
Amendment No. 4 to a Schedule 13D updates holdings and recent sales by Access Industries affiliates in Climb Bio, Inc. The Reporting Persons collectively own 3,835,117 shares, equal to 5.66% of the 67,764,100 shares outstanding as of
Susan Altschuller, Chief Financial Officer of Climb Bio, Inc. (CLYM), received a stock option grant on October 1, 2025. The option gives the right to buy 600,000 shares of common stock at an exercise price of $1.97 per share and is exercisable through September 30, 2035. The option vests 25% on the first anniversary of the grant and the remainder in 36 equal monthly installments through October 1, 2029, subject to continued service. The reported ownership following the grant is 600,000 shares, held directly.
Climb Bio, Inc. filed an 8-K reporting an employment-related material event involving Susan Altschuller. The filing references an Offer Letter dated
Schedule 13G: Pontifax-related entities report collective beneficial ownership of 5,206,380 shares of Climb Bio common stock, representing 7.7% of the class. The holdings are held in two limited partnerships (Pontifax (Israel) VI L.P. and Pontifax (Cayman) VI L.P.) controlled through Pontifax VI G.P. L.P. and Pontifax Management 4 G.P. (2015) Ltd., with Tomer Kariv and Ran Nussbaum identified as managing members. Reported power is shared voting and dispositive power over the full position; no sole voting or sole dispositive power is claimed.
FAQ
What is the current stock price of Climb Bio (CLYM)?
What is the market cap of Climb Bio (CLYM)?
